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Summary
In daily haematological practice, predicting bleeding in thrombocytopenic
patients is difficult, and clinicians adhere to transfusion triggers to guide
patients through the aplastic phase of chemotherapy. Platelet count is not
the only determinant of bleeding and additional mechanisms for impend-
ing haemostasis are likely. Beside clot formation, platelets are essential for
the maintenance of integrity of vascular beds. We therefore prospectively
investigated associations between biomarkers for endothelial damage (urine
albumin excretion) and inflammation (C-reactive protein) and bleeding
(WHO grading) in 88 patients with 116 on-protocol episodes. We found
an increase in grade 2 bleeding with a higher urine albumin/creatinine ratio
one day after the measurement [odds ratio (OR) 124 for every doubling of
the ratio, 95% CI 105–146, P-value 001] and a 29% increase in the odds
of grade 2 bleeding for every doubling of serum C-reactive protein (CRP)
(95% CI 104–160, P-value 002) after correction for morning platelet
count. The 24 h post-transfusion corrected count increment (CCI24)
showed a significant association with these biomarkers: increasing urine
albumin/creatinine ratio and CRP were associated with lower CCI24. We
report two inexpensive and easy-to-apply biomarkers that could be useful
in designing a prediction model for bleeding risk in thrombocytopenic
patients.
Keywords: haemorrhage, platelet transfusion, thrombocytopenia, microal-
buminuria, CRP.
Over 40% of patients with thrombocytopenia due to haema-
tological malignancy and intensive chemotherapy encounter
one or more bleeding episodes in a broad range of platelet
counts, despite trigger-based preventive platelet transfusion
practices (Heddle et al., 2009; Slichter et al., 2010; Ypma
et al., 2012; Stanworth et al., 2013). As the current prophy-
lactic trigger-based platelet transfusion strategy is associated
with adverse transfusion events, costs and resource issues
(Stanworth et al., 2015a), better strategies to identify patients
prone to bleeding are needed. Recently, the interest for on
demand therapeutic platelet transfusions has revived. Some
phenotypically “non-bleeding” patient conditions were iden-
tified, one of which is being in the thrombocytopenic phase
post-autologous stem cell transplantation (Wandt et al.,
2012; Stanworth et al., 2013). Despite the fact that some lab-
oratory tests are significantly associated with bleeding, such
as the absolute immature platelet count preluding the recov-
ery of functional platelets (Estcourt et al., 2014), the alpha
angle of thromboelastography (Opheim et al., 2017), a low
haematocrit (≤25%) and abnormal global coagulation assays
(Uhl et al., 2017), these tests are not commonly used in
transfusion practice.
research paper
ª 2019 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
doi: 10.1111/bjh.16291
Along with their haemostatic function, platelets con-
tribute to vascular integrity with a finite number of plate-
lets (Hanson & Slichter, 1985; Nachman & Rafii, 2008).
Spontaneous extravasation of red cells occurred in patients
with prolonged deep thrombocytopenia. In agreement with
this finding, a secondary analysis of the TOPPS study
revealed that a greater number of days with a platelet
count <10 9 109/l is associated with haemorrhage (Stan-
worth et al., 2015b). However, although a disturbed vascu-
lar lining is apparently an important risk for bleeding,
surprisingly, laboratory tests do not take vascular integrity
into account for transfusion management. In disorders with
endothelial disruption, such as diabetes mellitus type 2, an
important biomarker for endothelial damage is microalbu-
minuria, which is the loss of small amounts of albumin in
the urine (Stehouwer & Smulders, 2006; Martens et al.,
2018). Urine albumin excretion can be measured in a first
morning urine specimen and is either expressed as albumin
concentration (mg/l); daily albumin excretion in mg/24 h
or as the albumin/creatinine ratio (de Jong & Curhan,
2006). Whether urine albuminuria reflecting endothelial
damage enhances bleeding in the setting of a platelet defi-
cit in haematological malignancies has not been studied
before.
Fever is another risk factor for enhanced bleeding ten-
dency, as can be concluded from several clinical studies
(Webert et al., 2006; Stanworth et al., 2015b). Fever, when
resulting from inflammation and/or infection often leads to
increased C-reactive protein (CRP), which is a predictor of
bleeding severity in non-thrombocytopenic populations (Kol-
ler et al., 2015; Tomizawa et al., 2016).
The aim of this study was (1) to investigate whether
increased CRP levels and microalbuminuria, associated with
inflammation and vascular damage respectively in individuals
with normal platelet counts, also occur in thrombocytopenic
patients and (2) to test the hypothesis that these parameters
show an association with bleeding. The primary objective
was to evaluate whether these biomarkers show an associa-
tion with bleeding on the day of the measurement and the
two days thereafter. The secondary objective was to investi-
gate associations between the biomarkers and corrected
count increments after platelet transfusion.
Methods and materials
The study was designed as a prospective observational sub-
study in patients that were included in the PREPAReS trial.
This trial is registered at The Netherlands National Trial Reg-
istry as #NTR2106 and at www.clinicaltrials.gov as
#NCT02783313. PREPAReS was a randomized controlled
trial comparing pathogen-inactivated platelet concentrates
using riboflavin and ultraviolet (UV)-B illumination technol-
ogy (Mirasol, Terumo BCT, Lakewood, CO, USA) and
untreated, plasma-stored platelet concentrates in adult
patients ≥18 years old with haematological malignancies
requiring at least two platelet transfusions, and who had
signed informed consent (van der Meer et al., 2018). The
exclusion criteria were as follows: active bleeding at inclu-
sion, immunological refractoriness to platelet transfusions,
indications to use hyperconcentrated platelets, idiopathic
thrombocytopenic purpura, pregnancy, microangiopathic
thrombocytopenia, and known allergy to riboflavin or its
photoactive products (Ypma et al., 2016). The current study,
for which ethics approval was obtained, included patients in
four Dutch participating centres between January 2014 and
June 2016, irrespective of their treatment arm in the PRE-
PAReS trial. The principles of the Declaration of Helsinki
were adhered to. Included patients gave written informed
consent for laboratory assessments collected for the MARBLE
study (Microalbuminuria and bleeding complications in
patients with hypoproliferative thrombocytopenia). The study
observation period was from signing informed consent (usu-
ally one to several days before the first platelet transfusion)
until recovery from thrombocytopenia, hospital discharge, or
death. Patients could be included in the study more than
once in case of subsequent intensive chemotherapeutical
treatments, and inclusions will be referred to as “on-protocol
episodes”.
Analysis of urine and blood samples
All patients underwent measurement of urine and serum
biomarkers twice a week. In total, 438 measurements of
urine biomarkers and 462 measurements of CRP were car-
ried out. This encompassed the entire observation period,
including the period before the first transfusion. A variable
number of daily measurements was carried out per inclusion
depending on the duration of the study observation period.
The urinary measurement was performed in an overnight
first-voided urine sample. Urine albumin excretion is
expressed as urine albumin concentration (mg/l) and as
albumin/creatinine ratio (mg/mmol). Microalbuminuria is
defined as a urine albumin/creatinine ratio of 25–25 mg/
mmol for men and 35–35 mg/mmol for women (de Jong &
Curhan, 2006). Applying the ratio results in a somewhat
more reliable rendition of albuminuric subjects as compared
to that of the absolute urine albumin concentration (Bakker,
1999).
C-reactive protein was measured on the same days as the
urine albumin concentration and is expressed in mg/l. A
CRP of <3 mg/l is considered to be normal, 3–10 mg/l as
high-normal, and >10 mg/l as increased (Pepys & Hirsch-
field, 2003; Markanday, 2015). CRP and urinary albumin
were measured using a turbidimetric immunoassay at
340 nm (Cobas 6000, Roche Diagnostics, IN, USA). Urinary
creatinine was measured by the enzymatic Jaffe method
(Cobas 6000, Roche Diagnostics, IN, USA). A morning plate-
let count was performed 5–7 times a week according to stan-
dard procedures on a Sysmex XN1000 (Sysmex, Kobe,
Japan).
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Measurement of bleeding and body temperature
All patients underwent daily bleeding assessment (in total
1981 bleeding assessments) by independent research person-
nel. Bleeding symptoms were adjudicated afterwards by three
adjudicators who were blinded to the patient’s randomiza-
tion, and were categorized in grade 0–4 bleeding according
to the WHO bleeding scale (Slichter et al., 2010; Ypma et al.,
2016). For all patients, the morning temperature was mea-
sured daily (tympanic thermometry, Genius 2, Cardinal
Health Netherlands, Amsterdam, the Netherlands). A
temperature of ≥380°C is considered an increased body
temperature.
Transfusion increments
Post-transfusion corrected count increments were determined
1 h after platelet transfusion (CCI1) and after circa 24 h (18–
30 h after transfusion) (CCI24), corrected for number of pla-
telets transfused and body surface area (van der Meer et al.,
2018).
Multiple transfusions could be recorded on one day. If
both a pre- and a postcount were available for each transfu-
sion, they entered the analysis as separate transfusions. If no
separate precount for the second transfusion was available or
no postcount for the first transfusion, then one overall CCI
was calculated for both transfusions on that day, using the
sum of the doses given as the denominator. CCIs at one
hour generally have all pre- and postcounts, while for the
CCI at 24 h the approach of averaging multiple transfusions
was sometimes used.
Statistical analysis
Statistical analyses were performed with IBM SPSS Statistics
for Windows, version 23 (IBM Corp., Armonk, NY, USA).
All analyses were predetermined and were captured in a sta-
tistical analysis plan. The laboratory parameters (morning
platelet count, urine albumin/creatinine ratio and CRP) are
expressed as medians and interquartile range (IQR) or range.
To control for the impact of very high laboratory values for
urine albumin/creatinine ratio and serum CRP, the labora-
tory parameters were log2-transformed for further analysis.
The associations between laboratory parameters and bleeding
were tested using generalized linear mixed models with logit
link function taking into account dependent (within the
same patients) repeated measurements. In particular, two
random intercepts were included in the models, one account-
ing for multiple days (or multiple periods of two or
three days) within the same on-protocol episodes, and the
other accounting for multiple on-protocol episodes within
the same patient. First, univariable unadjusted odds ratios
for bleeding, together with 95% confidence intervals (CIs),
were estimated and tested. Next, the association between
urine albumin/creatinine ratio and CRP adjusted for platelet
count was estimated in two multivariable models. The urine
albumin/creatinine ratio and CRP were considered to be
potentially predictive for bleeding if a statistically significant
(a = 005) adjusted odds ratio would be found for bleeding
occurring the day of the measurement or 24–48 h after the
measurement using the multivariable analysis correcting for
platelet count. Of secondary interest was the association with
the measurement and bleeding outcome 48–72 h later. This
was separately performed for bleeding grade ≥1 and bleeding
grade 2. A sensitivity analysis was performed taking into
account two additional adjustment factors: fever and cardio-
vascular risk profile (one or more of the following comor-
bidities: hypertension, diabetes mellitus, TIA/CVA, peripheral
artery disease, ischaemic congestive heart failure, myocardial
infarction).
Associations between the urine albumin/creatinine ratio
and CCIs 1 h and 24 h after transfusions administered on
the first and the second day after the urine analysis were
tested using a general linear mixed model taking into
account non-independent (within same patients) repeated
measurements. The same associations were tested for CRP
and corrected count increments. Both the univariate unad-
justed regression coefficients and the coefficients after adjust-
ment for platelet count and randomisation arm in two
multivariable models were estimated. Urine albumin/crea-
tinine ratio and CRP were considered to be potentially asso-
ciated with CCI if there was a statistically significant
regression coefficient in the multivariable models.
Receiver operating characteristics curves were plotted to
compare sensitivity and specificity at different thresholds of
urine albumin/creatinine ratio and CRP with respect to
bleeding grade 2 the day after the measurement.
Results
The 116 on-protocol episodes analysed counted 88 patients
of whom 28 were included twice. The patient characteristics,
the number of laboratory measurements and the number of
days with bleeding observations in total and per thrombocy-
topenic episode are described in Table I. Platelet count
rapidly decreased by the day; at inclusion, 18% of patients
already had a low (<20 9 109/l) platelet count (Fig 1). The
distribution of the laboratory measurements over time is
shown in Fig 2 and Table SI. Both urine albumin excretion
and CRP built up to their maximum value around the 15th
day after chemotherapy (Fig 2, Table SI).
The patients received a total of 543 platelet transfusions.
Most of the platelet transfusions (86%) were administered
prophylactically at a trigger of 10 9 109/l, and 14% of all
platelets were either transfused therapeutically or to prevent
bleeding in case of an intervention at a trigger of 50 9 109/l.
There was no bleeding in 17% of all analysed on-protocol
episodes. In 40% of the episodes, the patient experienced a
grade 1 bleeding and in 43% a grade 2 bleeding was
observed. In none of the patients a grade 3 or grade 4
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bleeding occurred. The percentage of bleeding days per total
observed days was around 30% for bleeding grade ≥1 and
about 9 % for grade 2 bleeding.
Laboratory parameters and bleeding on the day of the
measurement and 1 and 2 days later
Platelet count. The univariable analyses for the association
between bleeding of grade ≥1 and platelet count showed that
a twofold lower platelet count was associated with a 32%
increased odds for bleeding on the day of the measurement
and a 29% increased odds for bleeding the day thereafter
(Table IIA, II). The platelet count was not significantly
associated with bleeding two days later; the odds ratio for
bleeding grade ≥1 was 092 (95% CI 081–104, P-value
019). For bleeding grade 2, doubling of the platelet count
was not significantly associated with the probability of bleed-
ing (Table IIA, II).
Urine albumin/creatinine ratio and CRP. Doubling of the
urine albumin/creatinine ratio was associated with a 13%
higher odds of bleeding grade ≥1 [odds ratio (OR) 113, 95%
CI 101–126, P-value 0027]. The association remained statis-
tically significant when adjusted for platelet count (OR 112,
95% CI 101–126, P = 0037). The analysis for the associa-
tion between bleeding grade ≥1 one day after measurement of
the urine albumin/creatinine ratio showed an increase in the
odds for bleeding of 15% (OR 115, 95% CI 104–129, P-
value 0009), adjustment for platelet count hardly changed
these results (OR 116, 95% CI 104–129, P = 0010,
Table IIA). Also, for bleeding grade 2, doubling of the urine
albumin/creatinine ratio was associated with a higher proba-
bility for bleeding the day after the measurement (adjusted
OR 124, 95% CI 105–146 and P = 0010, Table IIB), but
there was no association with bleeding two days later.
A higher value for CRP was significantly associated with a
higher probability of bleeding measured on the days of the lab-
oratory measurement, (both univariate and adjusted for plate-
let count) for grade ≥1 bleeding and grade 2 bleeding (18%
and 31% increase respectively). A significant 29% higher prob-
ability for grade 2 bleeding remained one day after the CRP
measurement, after adjusting for platelet count (Table IIB).
We performed sensitivity analyses and further corrected for
fever and vascular risk besides the former adjustment for plate-
let count, since these factors could influence the results for
CRP and urine albumin/creatinine ratio. The most important
finding was a persistent association between grade 2 bleeding
and doubling of urine albumin/creatinine ratio and CRP the
day before the bleeding [OR for urine albumin/creatinine ratio
(UACR) 127, 95% CI 106–152, P-value 0009 and OR for
CRP 139, 95% CI 108–178, P-value 0012] (Table IIB).
With respect to the receiver operating characteristics
curves that were plotted, the values for the AUC (area under
the curve) of urine albumin/creatinine ratio were higher than
for CRP (UACR AUC 0665 and CRP AUC 0642). The
curves, however, did not show a specific threshold for both
measurements.
Post-platelet transfusion Corrected Count Increments
Table III shows the associations between corrected count
increments and CRP and urine analysis. Corrected count
increments at 1 h and 24 h after platelet transfusions admin-
istered on the day of the measurement and one day later
were analysed. The associations after adjustment for random-
ization arm and platelet count are shown. The DCCI is a
negative value, which means that the CCI decreases with
increasing urine albumin/creatinine ratio or CRP. For the
urine albumin/creatinine ratio, a DCCI24 of 052, 95% CI
Table I. Patient characteristics. Patients could be included more than
once and an inclusion is referred to as “on-protocol episode”. A
variable number of observation days per inclusion are incorporated.
The cardiovascular risk profile is defined as one or more of the fol-
lowing comorbidities: hypertension, diabetes mellitus, TIA/CVA,
peripheral artery disease, ischemic congestive heart failure, or
myocardial infarction.
n = 116 on-protocol
episodes
Age [years; mean (SD)] 54 (12)
Gender (male/female; n/n) 75/41
Diagnosis n (%)
MDS/AML (myelodysplastic syndrome/
acute myeloid leukemia)
43 (37%)
MM (multiple myeloma) 33 (28%)
NHL (non hodgkin lymphoma) 27 (23%)
ALL (acute lymphoblastic leukemia) 6 (6%)
Other (Hodgkin’s lymphoma, mantle
cell lymphoma, chronic leukaemia)
7 (6%)
Treatment n (%)
Autologous transplantation 66 (57%)
Remission induction chemotherapy 32 (28%)
Consolidation chemotherapy 12 (10%)
Allogeneic transplantation 6 (5%)
Randomization arm in PREPAReS trial n (%)
Control (plasma stored
platelet concentrates)
57 (49%)
Intervention (pathogen-reduced
platelet concentrates)
59 (51%)
Number of observation days per
on-protocol episode median (IQR) with
Daily bleeding assessment 16 (12–20)
Measurement morning platelet count 13 (10–17)
Measurement urine
albumin/creatinine ratio
4 (2–5)
Measurement of serum
C-reactive protein
3 (2–5)
Cardiovascular risk profile present* n (%) 30 (286%)
Fever present n (%) of days 336 (295%)
ALL, acute lymphoblastic leukemia; IQR, interquartile range; MDS/
AML, myelodysplastic syndrome/acute myeloid leukemia; MM, mul-
tiple myeloma; NHL, non hodgkin lymphoma.
*Measurement available for 105/116 on-protocol episodes.
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093 to 011, P-value 0013 was observed, and for CRP
the DCCI24 was 10, 95% CI 167 to 032, P-value 0004
respectively. Corrected count increments at 1 h were signifi-
cantly associated with CRP measured on the day of or the
day before the transfusion (DCCI 065, 95% CI 109 to
0214, P-value 0004), whereas the urine albumin/creatinine
ratio was not (Table III). We found no association between
CCIs for transfusion administered 48 h after the measure-
ment of serum and urine biomarkers.
Discussion
This is the first study that prospectively collected and anal-
ysed (micro)albuminuria and CRP in patients with a
chemotherapy-induced platelet-deficient state and related
these biomarkers for endothelial dysfunction and inflamma-
tion to occurrence and severity of bleeding.
We studied 116 on-protocol episodes comprising
1981 days of bleeding assessments with 737 days with a
grade 1 (n = 401 days) or 2 bleeding (n = 168 days). A
two times higher morning platelet count was associated
with approximately 30% fewer grade 1 bleedings up to
24 h thereafter. However, grade 1 bleeding in the WHO
grading scale consists of relatively insignificant mucosal
and skin bleeds and poses no indication for platelet trans-
fusion. In clinical practice, grade 2 bleedings represent the
more clinically relevant bleedings elicited by minor trauma
or mucosal ulceration. In agreement with previous large
studies, the degree of thrombocytopenia had no effect on
grade 2 bleedings, suggesting that concomitant factors play
a role in the susceptibility for bleeding (Slichter et al.,
2010).
We found an association between microalbuminuria and
bleeding. Analyses with adjustment for the platelet count
showed that the urine albumin/creatinine ratio is associated
with grade 1 bleeding on the same day, and with grade 1
and 2 bleeding the day thereafter. For CRP, similar associa-
tions were found, which even remained present after correc-
tion for fever.
We assumed that albuminuria is a marker of generalised
microvascular endothelial alterations. This assumption has
been established indirectly in the literature concerning car-
diovascular disease (Stehouwer & Smulders, 2006), and has
only recently been proven more directly in the Maastricht
Study, where the association between experimentally induced
retinal arteriolar dilation and heat-induced skin hyperaemia
with 24-h albuminuria in a large population was studied
(Martens et al., 2018). In a pathological condition such as
diabetes mellitus, microalbuminuria is defined in a spot
urine sample or a first morning urine sample with a urine
albumin concentration of 20–200 mg/l (equivalent to an
albumin/creatinine ratio of 25–25 mg/mmol). An albumin
concentration of 10–20 mg/l (urine albumin/creatinine ratio
125–25 mg/mmol) was considered to be “high normal”,
while concentrations exceeding 200 mg/l (urine albumin/cre-
atinine ratio >25 mg/mmol) were regarded as macroalbu-
minuria (de Jong & Curhan, 2006). In the current cohort of
thrombocytopenic patients, up to 50% of all measurements
showed micro- or macroalbuminuria between days 15 and
24 after chemotherapy. Endothelial damage in our patients is
Fig 1. Morning platelet count: boxplots of median and interquartile range, maximum and minimum counts on days from chemotherapy.
[Colour figure can be viewed at wileyonlinelibrary.com]
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Fig 2. The distribution of laboratory measurements over time: urine albumin concentration (A); urine albumin/creatinine ratio (UACR) (B);
C-reactive protein (C). Only measurements of on-protocol episodes for which the date of first chemotherapy was known are shown. [Colour
figure can be viewed at wileyonlinelibrary.com]
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most likely multifactorial. A platelet-deficient state may con-
tribute to endothelial dysfunction because of a lack of repair-
ing capacity of the endothelium. Endothelial thinning has
been shown in an antibody-induced thrombocytopenia
model in rabbits; moreover earlier work in a limited patient
group showed marked endothelial thinning and an increase
in fenestrations in capillaries in skin and muscle biopsies of
patients with thrombocytopenia (Kitchens & Weiss 1975;
Kitchens & Pendergast, 1986). Also, an association with sev-
ere thrombocytopenia and leakage of 51Cr-labelled red cells
in the stool was shown in otherwise stable thrombocytopenic
patients (Slichter & Harker, 1978). A fixed amount of plate-
lets was shown to be necessary to preserve endothelial integ-
rity. A requirement of 71 platelets/µl/day (18% of the
normal rate of platelet turnover) was estimated from a model
after measuring platelet life span and platelet clearance at dif-
ferent platelet counts (Hanson & Slichter, 1985). The pres-
ence of bleeding despite maintenance of a platelet count of
>10 9 109/l is indicative of concomitant other factors. The
global endothelial dysfunction in this population may reflect
damage by chemotherapy (de Vos et al., 2004; Kvestad et al.,
2014). Similarly, inflammation and infection can cause
haemorrhage to become manifest in thrombocytopenia
(Goerge et al., 2008; Ho-Tin-Noe et al., 2018). As a biomar-
ker for local or generalised inflammation or infection, we
found CRP to be associated with bleeding in thrombocy-
topenic patients, independent of the presence of fever. This
is, to our knowledge, the first study to show this association
in patients with thrombocytopenia. C-reactive protein is an
acute phase protein, produced by the liver in response to
cytokines that are released from white blood cells. In several
non-thrombocytopenic patient groups, this was found to
represent a factor contributing to the bleeding risk (Koller
et al., 2015; Tomizawa et al., 2016). Both for CRP and urine
albumin, a late peak is seen in a small group of patients with
prolonged thrombocytopenia beyond 30 days. We suspect
these to be patients who live through a very complicated
phase with serious infection, but further confirmation is
required.
Corrected count increments measured 24 h after the trans-
fusion show an association with both urine albumin/crea-
tinine ratio and CRP. In line with the former reasoning, in
the condition of a deprived endothelium and a state of
inflammation, the consumption of larger amounts of plate-
lets could be a probable explanation; however, the effect of
transfusion itself on the urine and serum biomarkers is not
known. Associations between biomarkers of endothelial dam-
age and repair and platelet transfusion requirements have
been reported (McPherson et al., 2010), and these findings
also suggested that vascular regeneration is associated with
increased platelet consumption.
The strength of the current study is the carefully
observed cohort with daily uniform measurement of minor
and major bleeding complications as primary endpoint of
the PREPAReS trial, as well as having a pre-specified
analysis plan. The laboratory tests, urine albumin and
CRP, are rapidly and widely available and relatively inex-
pensive. A limitation of the study is the lack of more sev-
ere bleedings in the cohort. As has been mentioned by
other authors, the WHO bleeding scale does not necessar-
ily exclusively reflect increasing severity of bleedings from
grade 1 to grade 4, but possibly designates bleeding types
with differing pathogenesis (Heddle et al., 2010). Since
WHO grade 3 and 4 bleeding was not observed in our
cohort, we do not know whether the biomarkers tested
also show an association with higher bleeding grades. Fur-
ther, receiving chemotherapy may confound the study out-
comes, and studies in non-thrombocytopenic patients that
receive chemotherapy may shed further light on this. The
associations between biomarkers and bleeding that we
found were moderately strong. The markers on their own
will not be perfect predictors of bleeding. Also, the relative
contribution of platelet transfusion to the associations
between urine albumin/creatinine ratio, CRP and bleeding
is unknown. Larger studies are needed to rule out transfu-
sions as a confounder.
In conclusion, the occurrence and quantity of albuminuria
and CRP in thrombocytopenic patients are associated with a
bleeding phenotype as well as with increased platelet con-
sumption as shown by lower CCIs after platelet transfusions.
How these biomarkers can be incorporated into a model to
predict which patient will develop a clinically significant
bleeding requiring additional platelet transfusion support or
alternative strategies such as antifibrinolytic agents, remains
to be studied.
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Table SI. The distribution of laboratory measurements
over time: urine albumin concentration (A); urine albumin/
creatinine ratio (UACR) (B); C-reactive protein (C). Only
measurements of on-protocol episodes for which the date of
first chemotherapy was known are shown (n = number of
observations).
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